It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Facility designed to advance the next generation of imaging systems
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Subscribe To Our Newsletter & Stay Updated
